# Gene expression in bladder cancer and normal tissues

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>
21/12/2024	No longer recruiting	☐ Protocol
Registration date 26/02/2025	Overall study status Completed	Statistical analysis plan
		Results
Last Edited	Condition category	Individual participant data
06/01/2025	Cancer	[X] Record updated in last year

# Plain English summary of protocol

Background and study aims

In this study, patients with bladder cancer were examined to analyze the levels of RBM15 in both cancerous and normal tissues. The goal was to identify potential therapeutic targets that could be used to treat bladder cancer more effectively.

Who can participate?

Patients diagnosed with bladder cancer

What does the study involve?

Participants joined the study starting in March 2018 and for 6 years. This study collects tissue samples at the time of surgery and follows participants for 6 years. Patients are followed up annually by telephone for survival. Cancerous and normal tissues were collected from patients with bladder cancer.

What are the possible benefits and risks of participating?

The study team provided 1000 RMB as compensation for each patient. In this study, the discarded tumor tissue was removed during the patient's operation, which did not affect the body and no other participation risks were anticipated.

Where is the study run from?

The study was conducted in Affiliated Haikou Hospital of Xiangya Medical College

When is the study starting and how long is it expected to run for? March 2022 to June 2024

Who is funding the study?

- 1. Finance Science and Technology Project of Hainan Province
- 2. National Science Foundation of China
- 3. Health Department of Hainan Province

Who is the main contact? Shufang Zhang, zsf 99900023@csu.edu.cn

# Contact information

# Type(s)

Public, Scientific, Principal Investigator

# Contact name

Prof Shufang Zhang

# **ORCID ID**

https://orcid.org/0009-0000-7203-665X

# Contact details

No.43 Renmin Avenue Haikou China 570208 +86 089866289665 zsf 99900023@csu.edu.cn

# Type(s)

Public, Principal Investigator

#### Contact name

Dr Mei Chen

# Contact details

No.43 Renmin Avenue Haikou China 570208 +86 15243653187 meichen\_cns@163.com

# Additional identifiers

# EudraCT/CTIS number

Nil known

# **IRAS** number

# ${\bf Clinical Trials. gov\ number}$

Nil known

# Secondary identifying numbers

CPMS2023

# Study information

Scientific Title

#### Bladder cancer and normal tissues

# Study objectives

Expression of RBM15 in bladder cancer and normal tissue

# Ethics approval required

Ethics approval required

# Ethics approval(s)

Approved 10/03/2022, Haikou Municipal People's Hospital Biomedical Ethics Committee (No.43 Renmin Avenue, Haikou, 570208, China; +86 089866189665; zsf66189665@126.com), ref: 2023-055

# Study design

Observational cohort study

# Primary study design

Observational

# Secondary study design

Cohort study

# Study setting(s)

Internet/virtual, Laboratory, Telephone

# Study type(s)

Treatment

#### Participant information sheet

No participant information sheet available

# Health condition(s) or problem(s) studied

Bladder cancer

#### **Interventions**

This study enrols patients with bladder cancer, collects tissue samples at the time of surgery, and follows them for 6 years. Patients are followed up annually by telephone for survival.

Cancerous and normal tissues were collected from patients with bladder cancer.

# Intervention Type

Other

#### Primary outcome measure

Survival measured using data collected at an annual telephone call for 6 years

# Secondary outcome measures

Transfer or not measured using data collected during a telephone call every 6 months

# Overall study start date

# Completion date

12/06/2024

# **Eligibility**

# Key inclusion criteria

Patients who were diagnosed with bladder cancer

# Participant type(s)

**Patient** 

# Age group

Mixed

# Sex

Both

# Target number of participants

67

# Key exclusion criteria

Patients with other cancers

# Date of first enrolment

11/05/2022

# Date of final enrolment

01/06/2024

# Locations

# Countries of recruitment

China

# Study participating centre Affiliated Haikou Hospital of Xiangya Medical College

No.43 Renmin Avenue Haikou China 570208

# Sponsor information

# Organisation

Affiliated Haikou Hospital of Xiangya Medical College

# Sponsor details

No.43 Renmin Avenue Haikou China 570208 +86 089866189663 zsf66189665@126.com

# Sponsor type

Hospital/treatment centre

# Website

https://www.haikoumh.com.cn/

# Funder(s)

# Funder type

Government

# **Funder Name**

Hainan Provincial Department of Science and Technology

# Alternative Name(s)

, Department of Science and Technology of Hainan Province

# **Funding Body Type**

Government organisation

# **Funding Body Subtype**

Local government

# Location

China

#### **Funder Name**

National Natural Science Foundation of China

# Alternative Name(s)

Chinese National Science Foundation, Natural Science Foundation of China, National Science Foundation of China, NNSF of China, NSF of China, National Nature Science Foundation of China, Guójiā Zìrán Kēxué Jījīn Wěiyuánhuì, NSFC, NNSF, NNSFC

# **Funding Body Type**

Government organisation

# **Funding Body Subtype**

National government

#### Location

China

# Funder Name

Hainan Provincial Department of Health

# Alternative Name(s)

, Department of Health, Hainan Province, Hainan Health Department

# **Funding Body Type**

Government organisation

# **Funding Body Subtype**

Local government

#### Location

China

# **Results and Publications**

# Publication and dissemination plan

Planned publication in a peer-reviewed journal

# Intention to publish date

12/06/2025

# Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from Shufang Zhang, zsf\_99900023@csu.edu.cn

# IPD sharing plan summary

Available on request